FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Kufer

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Procedures

Immunotherapy

Disorders

Neoplasms

Co-author Network

Publications

TOP 3
Max S Topp; Andreas Viardot; Gerhard Zugmaier; Patrick A Baeuerle; Monika Brüggemann; Thomas Burmeister; Evelyn Degenhard; Hermann Einsele; Marie-Elisabeth Goebeler; Nicola Gökbuget; Dieter Hoelzer; Heinz A Horst; Matthias Klinger; Michael Kneba; Rudolf Köhne-Volland; Peter Kufer; Dirk Nagorsen; Svenja A Neumann; Oliver G Ottmann; Thorsten Raff; Gert Riethmüller; Markus Schaich; Margit Schmidt; Matthias Stelljes; Ralf C Bargou
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Matthias Friedrich; Melanie Fuergut; Patrick Hoffmann; Roman Kischel; Patrick A Baeuerle; Christian Brandl; Petra Deegen; Ricarda Finnern; Ralf Lutterbuese; Peter Mueller; Benno Rattel; Doris Rau; Tobias Raum; Joachim Schuhmacher; Jerry W Slootstra; Markus Voelkel; Dieter Zopf; Peter Kufer
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Blinatumomab: a historical perspective.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Kufer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Max S Topp; Andreas Viardot; Gerhard Zugmaier; Patrick A Baeuerle; Monika Brüggemann; Thomas Burmeister; Evelyn Degenhard; Hermann Einsele; Marie-Elisabeth Goebeler; Nicola Gökbuget; Dieter Hoelzer; Heinz A Horst; Matthias Klinger; Michael Kneba; Rudolf Köhne-Volland; Peter Kufer; Dirk Nagorsen; Svenja A Neumann; Oliver G Ottmann; Thorsten Raff; Gert Riethmüller; Markus Schaich; Margit Schmidt; Matthias Stelljes; Ralf C Bargou
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Blood 2012;120(26):5185-7.
2012: Matthias Friedrich; Melanie Fuergut; Patrick Hoffmann; Roman Kischel; Patrick A Baeuerle; Christian Brandl; Petra Deegen; Ricarda Finnern; Ralf Lutterbuese; Peter Mueller; Benno Rattel; Doris Rau; Tobias Raum; Joachim Schuhmacher; Jerry W Slootstra; Markus Voelkel; Dieter Zopf; Peter Kufer
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Molecular cancer therapeutics 2012;11(12):2664-73.
2012: Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Blinatumomab: a historical perspective.
Pharmacology & therapeutics 2012;136(3):334-42.
2012: Matthias Klinger; Dirk Nagorsen; Svenja Neumann; Matthias Stelljes; Max S Topp; Andreas Viardot; Andreas Wolf; Gerhard Zugmaier; Patrick A Baeuerle; Ralf C Bargou; Christian Brandl; Monika Brüggemann; Evelyn Degenhard; Mariele Goebeler; Nicola Gökbuget; Youssef Hijazi; Dieter Hoelzer; Peter Kufer
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood 2012;119(26):6226-33.
2011: Max S Topp; Andreas Viardot; Gerhard Zugmaier; Patrick A Baeuerle; Monika Brüggemann; Thomas Burmeister; Evelyn Degenhard; Hermann Einsele; Mariele Goebeler; Nicola Gökbuget; Dieter Hoelzer; Heinz-A Horst; Matthias Klinger; Michael Kneba; Rudolf Köhne-Volland; Peter Kufer; Ralf Lutterbuese; Dirk Nagorsen; Svenja Neumann; Oliver Ottmann; Heike Pfeifer; Thorsten Raff; Carsten Reinhardt; Gert Riethmüller; Markus Schaich; Mathias Schmid; Margit Schmidt; Matthias Stelljes; Ralf C Bargou
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(18):2493-8.
2010: Claudia Bluemel; Susanne Hausmann; Petra Fluhr; Mirnalini Sriskandarajah; William B Stallcup; Patrick A Baeuerle; Peter Kufer
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Cancer immunology, immunotherapy : CII 2010;59(8):1197-209.
2010: Ralf Lutterbuese; Tobias Raum; Roman Kischel; Patrick Hoffmann; Susanne Mangold; Benno Rattel; Matthias Friedrich; Oliver Thomas; Grit Lorenczewski; Doris Rau; Evelyne Schaller; Ines Herrmann; Andreas Wolf; Thomas Urbig; Patrick A Baeuerle; Peter Kufer
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(28):12605-10.
2010: Cory L Brooks; Andrea Schietinger; Svetlana N Borisova; Peter Kufer; Mark Okon; Tomoko Hirama; C Roger MacKenzie; Lai-Xi Wang; Hans Schreiber; Stephen V Evans
Antibody recognition of a unique tumor-specific glycopeptide antigen.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(22):10056-61.
2010: Markus Münz; Alexander Murr; Majk Kvesic; Doris Rau; Susanne Mangold; Stefan Pflanz; John Lumsden; Jörg Volkland; Jan Fagerberg; Gert Riethmüller; Dominik Rüttinger; Peter Kufer; Patrick A Baeuerle; Tobias Raum
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Cancer cell international 2010;10():44.
2010: Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.
PloS one 2010;5(10):e13474.
2009: Maria Amann; Sandrine D'Argouges; Grit Lorenczewski; Klaus Brischwein; Roman Kischel; Ralf Lutterbuese; Susanne Mangold; Doris Rau; Jörg Volkland; Stefan Pflanz; Tobias Raum; Markus Münz; Peter Kufer; Bernd Schlereth; Patrick A Baeuerle; Matthias Friedrich
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(5):452-64.
2009: Dirk Nagorsen; Ralf Bargou; Dominik Ruttinger; Peter Kufer; Patrick A Baeuerle; Gerhard Zugmaier
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Leukemia & lymphoma 2009;50(6):886-91.
2009: Ralf Lutterbuese; Tobias Raum; Roman Kischel; Petra Lutterbuese; Bernd Schlereth; Evelyne Schaller; Susanne Mangold; Doris Rau; Petra Meier; Peter Kiener; Kathy A Mulgrew; Michael D Oberst; Scott A Hammond; Patrick A Baeuerle; Peter Kufer
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(4):341-52.
2009: Jutta Steigerwald; Tobias Raum; Stefan Pflanz; Ronny Cierpka; Susanne Mangold; Doris Rau; Patrick Hoffmann; Majk Kvesic; Christina Zube; Stefanie Linnerbauer; John Lumsden; Mirnaalini Sriskandarajah; Peter Kufer; Patrick A Baeuerle; Jörg Volkland
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.
mAbs 2009;1(2):115-27.
2009: Sandrine d'Argouges; Sandra Wissing; Christian Brandl; Nadja Prang; Ralf Lutterbuese; Alexander A Kozhich; JoAnn A Suzich; Mathias Locher; Peter Kiener; Peter Kufer; Robert Hofmeister; Patrick A Baeuerle; Ralf C Bargou
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
Leukemia research 2009;33(3):465-73.
2009: Patrick A Baeuerle; Peter Kufer; Ralf Bargou
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Current opinion in molecular therapeutics 2009;11(1):22-30.
2009: Cornelia Haas; Eva Krinner; Klaus Brischwein; Patrick Hoffmann; Ralf Lutterbüse; Bernd Schlereth; Peter Kufer; Patrick A Baeuerle
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Immunobiology 2009;214(6):441-53.
2009: Maria Amann; Matthias Friedrich; Petra Lutterbuese; Eva Vieser; Grit Lorenczewski; Laetitia Petersen; Klaus Brischwein; Peter Kufer; Roman Kischel; Patrick A Baeuerle; Bernd Schlereth
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Cancer immunology, immunotherapy : CII 2009;58(1):95-109.
2008: Ralf C Bargou; Eugen Leo; Gerhard Zugmaier; Matthias Klinger; Mariele Goebeler; Stefan Knop; Richard Noppeney; Andreas Viardot; Georg Hess; Martin Schuler; Hermann Einsele; Christian Brandl; Andreas Wolf; Petra Kirchinger; Petra Klappers; Margit Schmidt; Gert Riethmüller; Carsten Reinhardt; Patrick A Baeuerle; Peter Kufer
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Science (New York, N.Y.) 2008;321(5891):974-7.
2008: Maria Amann; Klaus Brischwein; Petra Lutterbuese; Larissa Parr; Laetitia Petersen; Grit Lorenczewski; Eva-Maria Krinner; Sandra Bruckmeier; Sandra Lippold; Roman Kischel; Ralf Lutterbuese; Peter Kufer; Patrick A Baeuerle; Bernd Schlereth
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Cancer research 2008;68(1):143-51.
2007: Klaus Brischwein; Larissa Parr; Stefan Pflanz; Jörg Volkland; John Lumsden; Matthias Klinger; Mathias Locher; Scott A Hammond; Peter Kiener; Peter Kufer; Bernd Schlereth; Patrick A Baeuerle
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):798-807.
2007: Christian Brandl; Cornelia Haas; Sandrine d'Argouges; Tanja Fisch; Peter Kufer; Klaus Brischwein; Nadja Prang; Ralf C Bargou; JoAnn A Suzich; Patrick A Baeuerle; Robert Hofmeister
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Cancer immunology, immunotherapy : CII 2007;56(10):1551-63.
2007: Ingo Mecklenburg; Dorothea Weckermann; Alfred Zippelius; Alexandra Schoberth; Stephanie Petersen; Nadja Prang; Gert Riethmüller; Peter Kufer
A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.
Journal of immunological methods 2007;323(2):180-93.
2007: Scott A Hammond; Ralf Lutterbuese; Shannon Roff; Petra Lutterbuese; Bernd Schlereth; Elizabeth M Bruckheimer; Michael S Kinch; Steven R Coats; Patrick A Baeuerle; Peter Kufer; Peter Kiener
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Cancer research 2007;67(8):3927-35.
2007: Michael Mølhøj; Sandrine Crommer; Klaus Brischwein; Doris Rau; Mirnaalini Sriskandarajah; Patrick Hoffmann; Peter Kufer; Robert Hofmeister; Patrick A Baeuerle
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Molecular immunology 2007;44(8):1935-43.
2006: Eva-Maria Krinner; julia hepp; Patrick Hoffmann; Sandra Bruckmaier; Laetitia Petersen; Silke Petsch; Larissa Parr; Ioana Schuster; Susanne Mangold; Grit Lorenczewski; Petra Lutterbüse; Stefan Buziol; Inessa Hochheim; Jörg Volkland; Michael Mølhøj; Mirnaalini Sriskandarajah; Markus Strasser; Christian Itin; Andreas Wolf; Amartya Basu; Karen Yang; David Filpula; Poul Sørensen; Peter Kufer; Patrick A Baeuerle; Tobias Raum
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.
Protein engineering, design & selection : PEDS 2006;19(10):461-70.
2006: Juergen M Schanzer; Iduna Fichtner; Patrick A Baeuerle; Peter Kufer
Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(5):477-88.
2006: Bernd Schlereth; Petra Kleindienst; Iduna Fichtner; Grit Lorenczewski; Klaus Brischwein; Sandra Lippold; Antonio da Silva; Mathias Locher; Roman Kischel; Ralf Lutterbüse; Peter Kufer; Patrick A Baeuerle
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Cancer immunology, immunotherapy : CII 2006;55(7):785-96.
2006: Bernd Schlereth; Cornelia Quadt; Torsten Dreier; Peter Kufer; Grit Lorenczewski; Nadja Prang; Christian Brandl; Sandra Lippold; Kathy Cobb; Kathleen M Brasky; Eugen Leo; Ralf C Bargou; Krishna K Murthy; Patrick A Baeuerle
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Cancer immunology, immunotherapy : CII 2006;55(5):503-14.
2006: Klaus Brischwein; Bernd Schlereth; Benjamin Guller; Carola Steiger; Andreas Wolf; Ralf Lutterbuese; Sonja Offner; Mathias Locher; Thomas Urbig; Tobias Raum; Petra Kleindienst; Pauline Wimberger; Rainer Kimmig; Iduna Fichtner; Peter Kufer; Robert Hofmeister; Antonio J da Silva; Patrick A Baeuerle
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Molecular immunology 2006;43(8):1129-43.
2006: Sonja Offner; Robert Hofmeister; Andrea Romaniuk; Peter Kufer; Patrick A Baeuerle
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Molecular immunology 2006;43(6):763-71.
2006: Juergen M Schanzer; Patrick A Baeuerle; Torsten Dreier; Peter Kufer
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Cancer immunity 2006;6():4.
2005: Matthias Mack; Jochen Pfirstinger; Jürgen Haas; Peter J Nelson; Peter Kufer; Gert Riethmüller; Detlef Schlöndorff
Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infection.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7586-93.
2005: Evelyn Wolf; Robert Hofmeister; Peter Kufer; Bernd Schlereth; Patrick A Baeuerle
BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Drug discovery today 2005;10(18):1237-44.
2005: Ines Mende; Patrick Hoffmann; Andreas Wolf; Ralf Lutterbüse; Eugen Kopp; Patrick A Baeuerle; Annegret de Baey; Peter Kufer
Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugates.
International immunology 2005;17(5):539-47.
2005: Sonja Offner; Armin Hekele; Ulrike Teichmann; Susanne Weinberger; Susanne Gross; Peter Kufer; Christian Itin; Patrick A Baeuerle; Birgit Kohleisen
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy.
Cancer immunology, immunotherapy : CII 2005;54(5):431-45.
2005: Bernd Schlereth; Iduna Fichtner; Grit Lorenczewski; Petra Kleindienst; Klaus Brischwein; Antonio da Silva; Peter Kufer; Ralf Lutterbuese; Ilse Junghahn; Sabine Kasimir-Bauer; Pauline Wimberger; Rainer Kimmig; Patrick A Baeuerle
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Cancer research 2005;65(7):2882-9.
2004: Peter Kufer; Ralf Lutterbüse; Patrick A Baeuerle
The promise of bispecific antibodies.
Discovery medicine 2004;4(23):325-32.
2004: Ingo Mecklenburg; Diana F Stratakis; Rudolf M Huber; Karl Häußinger; Alicia Morresi-Hauf; Gert Riethmüller; Peter Kufer
Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer.
Chest 2004;125(5 Suppl):164S-6S.
2004: Peter Kufer; Ralf Lutterbüse; Patrick A Baeuerle
A revival of bispecific antibodies.
Trends in biotechnology 2004;22(5):238-44.
2004: Dirk Hönemann; Peter Kufer; M M Rimpler; Manik Chatterjee; S Friedl; F Riecher; Kurt Bommert; Bernd Dörken; Ralf C Bargou
A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Leukemia 2004;18(3):636-44.
2003: Patrick A Baeuerle; Peter Kufer; Ralf Lutterbüse
Bispecific antibodies for polyclonal T-cell engagement.
Current opinion in molecular therapeutics 2003;5(4):413-9.
2003: A Löffler; M Gruen; Christian Wuchter; F Schriever; Peter Kufer; Torsten Dreier; Frank Hanakam; Patrick A Baeuerle; Kurt Bommert; Leonid Karawajew; Bernd Dörken; Ralf C Bargou
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Leukemia 2003;17(5):900-9.
2003: Torsten Dreier; Patrick A Baeuerle; Iduna Fichtner; Michael Grün; Bernd Schlereth; Grit Lorenczewski; Peter Kufer; Ralf Lutterbüse; Gert Riethmüller; Per Gjorstrup; Ralf C Bargou
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(8):4397-402.
2002: Torsten Dreier; Grit Lorenczewski; Christian Brandl; Patrick Hoffmann; Uwe Syring; Frank Hanakam; Peter Kufer; Gert Riethmuller; Ralf C Bargou; Patrick A Baeuerle
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
International journal of cancer. Journal international du cancer 2002;100(6):690-7.
2002: Stefanie Naundorf; Susanne Preithner; Petra Mayer; Sandra Lippold; Andreas Wolf; Frank Hanakam; Iduna Fichtner; Peter Kufer; Tobias Raum; Gert Riethmüller; Patrick A Baeuerle; Torsten Dreier
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
International journal of cancer. Journal international du cancer 2002;100(1):101-10.
2002: Peter Kufer; Alfred Zippelius; Ralf Lutterbüse; Ingo Mecklenburg; Thomas Enzmann; Anthony Montag; Dorothea Weckermann; Bernward Passlick; Nadja Prang; Peter Reichardt; Martin Dugas; Manfred W Köllermann; Klaus Pantel; Gert Riethmüller
Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
Cancer research 2002;62(1):251-61.
2001: Peter Kufer; F Zettl; K Borschert; Ralf Lutterbüse; Roman Kischel; Gert Riethmüller
Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.
Cancer immunity 2001;1():10.
2001: Konstantin Maletz; Peter Kufer; Matthias Mack; Tobias Raum; Klaus Pantel; Gert Riethmüller; R Gruber
Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
International journal of cancer. Journal international du cancer 2001;93(3):409-16.
2001: Tobias Raum; R Gruber; Gert Riethmüller; Peter Kufer
Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens.
Cancer immunology, immunotherapy : CII 2001;50(3):141-50.
2000: A Löffler; Peter Kufer; Ralf Lutterbüse; F Zettl; Peter Daniel; J M Schwenkenbecher; Gert Riethmüller; Bernd Dörken; Ralf C Bargou
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Blood 2000;95(6):2098-103.
1997: Peter Kufer; Matthias Mack; R Gruber; Ralf Lutterbüse; F Zettl; Gert Riethmüller
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Cancer immunology, immunotherapy : CII 1997;45(3-4):193-7.
1997: Alfred Zippelius; Peter Kufer; G Honold; Manfred W Köllermann; Ralph Oberneder; Günter Schlimok; Gert Riethmüller; Klaus Pantel
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2701-8.
1997: M Mack; R Gruber; S Schmidt; Gert Riethmüller; Peter Kufer
Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(8):3965-70.
1996: M Rheinnecker; C Hardt; Leodevico L Ilag; Peter Kufer; R Gruber; A Hoess; A Lupas; C Rottenberger; A Plückthun; P Pack
Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(7):2989-97.
1995: Matthias Mack; Gert Riethmüller; Peter Kufer
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(15):7021-5.
1995: S Krauss; Peter Kufer; C Federle; P Tabaszewski; E Weiss; E Peter Rieber; Gert Riethmüller
Recombinant CD4-IgE, a novel hybrid molecule, inducing basophils to respond to human immunodeficiency virus (HIV) and HIV-infected target cells.
European journal of immunology 1995;25(1):192-9.
1992: Hans A Kretzschmar; Peter Kufer; Gert Riethmüller; S DeArmond; Stanley B Prusiner; D Schiffer
Prion protein mutation at codon 102 in an Italian family with Gerstmann-Sträussler-Scheinker syndrome.
Neurology 1992;42(4):809-10.